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Airflow limitation in COPD patients is not fully reversible. However, there may be large vari-
ability in bronchodilator responsiveness (BDR) among COPD patients, and familial aggregation
of BDR suggests a genetic component. Therefore, we investigated the association between
six candidate genes and BDR in subjects with severe COPD. A total of 389 subjects from the
National Emphysema Treatment Trial (NETT) were analyzed. Bronchodilator responsiveness
to albuterol was expressed in three ways: absolute change in FEV1, change in FEV1 as a percent
of baseline FEV1, and change in FEV1 as a percent of predicted FEV1. Genotyping was completed
for 122 single nucleotide polymorphisms (SNPs) in six candidate genes (EPHX1, SFTPB, TGFB1,
SERPINE2, GSTP1, ADRB2). Associations between BDR phenotypes and SNP genotypes were
tested using linear regression, adjusting for age, sex, pack-years of smoking, and height. Genes
associated with BDR phenotypes in the NETT subjects were assessed for replication in 127 pedi-
grees from the Boston Early-Onset COPD (EOCOPD) Study. Three SNPs in EPHX1 (pZ 0.009e
0.04), three SNPs in SERPINE2 (pZ 0.004e0.05) and two SNPs in ADRB2 (0.04e0.05) were signif-
icantly associated with BDR phenotypes in NETT subjects. One SNP in EPHX1 (rs1009668,
pZ 0.04) was significantly replicated in EOCOPD subjects. SNPs in SFTPB, TGFB1, and GSTP1
genes were not associated with BDR. In conclusion, a polymorphism of EPHX1 was associated
with bronchodilator responsiveness phenotypes in subjects with severe COPD.
ª 2008 Elsevier Ltd. All rights reserved.Laboratory, Brigham and
nue, Boston, MA 02115, USA.
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Chronic obstructive pulmonary disease (COPD) is charac-
terized by airflow limitation that is not fully reversible;
however, COPD patients are often treated with.
Genetic influences on BDR 553bronchodilator medications.1 There is large variability in
bronchodilator responsiveness (BDR) among COPD patients,
which has been related to various factors such as age,2
smoking,3 baseline lung function,4 and eosinophil
biomarkers in bronchoalveolar lavage fluid.5 These findings
suggest that differences in disease characteristics of COPD
subjects may be associated with interindividual variation in
pharmacological response to bronchodilator medications.
A previous paper found significant familial aggregation
of BDR in the Boston Early-Onset COPD Study,6 suggesting
the effect of genetic factors. Recent studies revealed that
polymorphisms in hemopoeitic cell kinase (HCK )7 and b2-
adrenergic receptor genes8 may be associated with BDR in
patients with COPD. However, the genetic determinants
of BDR in COPD have not been definitively established.
Glutathione s-transferase pi 1 (GSTP1), microsomal
epoxide hydrolase (EPHX1), transforming growth factor-b1
(TGFB1), serpin peptidase inhibitor clade E member 2
(SERPINE2), surfactant protein B (SFTPB) and b2-adrenergic
receptor (ADRB2) are six candidate genes previously asso-
ciated with COPD susceptibility in at least two studies.9e13
ADRB2 has been associated with BDR in subjects with
asthma and COPD.8,14 We hypothesized that genetic vari-
ants in these potential COPD susceptibility genes may
explain some of the variability in bronchodilator respon-
siveness phenotypes. This may improve our understanding
of COPD by identifying subsets of patients showing small or
large bronchodilator responsiveness influenced by a partic-
ular COPD susceptibility gene. Therefore, we investigated
the association between six candidate genes and BDR in two
populations of subjects with severe COPD.
Methods
Subjects
The current analysis included 389 non-Hispanic white
subjects in the National Emphysema Treatment Trial
(NETT).15 Subjects enrolled in NETT had severe airflow
obstruction (FEV1 45% predicted), hyperinflation, andTable 1 Baseline characteristics of 389 subjects in the National
subjects in the Boston Early-Onset COPD Study. Data are present
Variable NETT
Number 389
Male (%) 250 (64.3)
Age, years 67.4 5.8
Smoking, pack-years 66.4 30.4




a BDRABSZ postbronchodilator FEV1 prebronchodilator FEV1.
b BDRBASEZðpostbronchodilator FEV1prebronchodilator FEV1Þprebronchodilator FEV1  100
c BDRPREDZðpostbronchodilator FEV1prebronchodilator FEV1Þpredicted prebronchodilator FEV1  100bilateral emphysema on high-resolution chest CT. Spirom-
etry was performed according to American Thoracic Society
(ATS) standards before and after administration of 2 puffs
(180 mcg) of inhaled albuterol.16 CT analysis on NETT
subjects has been described previously.17
Genes associated with BDR phenotypes in the NETT
subjects were examined in participants in the Boston Early-
Onset COPD Study. Enrollment of subjects and phenotyping
in the Boston Early-Onset COPD Study have been described
previously.18 Spirometry was performed in accordance with
ATS specifications before and after inhalation of 2 puffs
(180 mcg) of albuterol using a spacer device. Extended
pedigrees were ascertained through probands under 53
years old with COPD with FEV1< 40% predicted. The current
analysis included 949 subjects in 127 pedigrees.
Both studies were approved by institutional review
boards at participating centers. All subjects provided
written informed consent.
Genotyping
Genotyping was done for 122 single nucleotide poly-
morphisms (SNPs) in six candidate genes (19 in EPHX1, 5 in
SFTPB, 21 in TGFB1, 64 in SERPINE2, 7 in GSTP1, 6 in ADRB2)
including upstream and downstream genomic regions. We
used pairwise linkage disequilibrium (LD)-tagging in Tagger
with19 minimum minor allele frequency of 0.10 and r2-
threshold of 0.9, based on genotype data from Caucasian
(CEU) trios in Phase II of the HapMap Project.20 Additional
SNPs were also genotyped, based on previously reported
genetic association analyses of COPD-related phenotyp-
es.9e11 SNPs were genotyped using TaqMan (Applied Bio-
systems, Foster City, CA) or Sequenom (San Diego, CA)
assays as previously reported.21,22
Statistical analysis
Response to albuterol was expressed in three ways: absolute
change in FEV1 [BDRABSZ postbronchodilator FEV1 pre-
bronchodilator FEV1], change in FEV1 as a percent ofEmphysema Treatment Trial Genetics Ancillary Study and 949
ed as means (S.D.), unless otherwise noted.






32 (25.2) 216 (42.9) 148 (46.4)
48.1 4.7 42.0 17.9 52.9 18.2
38.9 21.9 17.3 23.9 21.6 26.5
19.2 7.4 83.3 21.9 84.9 19.1
0.09 0.07 0.11 0.14 0.09 0.13
16.1 13.5 4.9 7.3 4.4 6.6
3.0 2.6 3.3 4.2 3.1 3.9
554 W.J. Kim et al.baseline FEV1 [BDRBASEZ ((postbronchodilator FEV1 pre-
bronchodilator FEV1)/prebronchodilator FEV1) 100], and
change in FEV1 as a percent of predicted FEV1
[BDRPREDZ ((postbronchodilator FEV1 prebronchodilator
FEV1)/predicted FEV1) 100].
In NETT, associations between the three BDR phenotypes
and SNP genotypes were tested using linear regression,
adjusting for age, sex, and pack-years of smoking, assuming
additive genetic models. Models for BDRABS were addi-
tionally adjusted for height. Analyses were conducted using
SAS 9.1 (SAS Institute, Cary, NC). Association between
haplotypes and BDR phenotypes in NETT subjects was
tested using haplo.stats.23 In the Boston Early-Onset COPD
Study, family-based association analysis was performed
using PBAT software version 3.524 assuming additive genetic
models, adjusting for age, sex, and pack-years of smoking.
Models for BDRABS were additionally adjusted for height. A
p-value 0.05 was used to define a statistically significant
result.
Results
Baseline characteristics of subjects
The mean age of NETT subjects was 67.4 years, and mean
baseline prebronchodilator FEV1 was 24.8% predicted.
Mean BDRABS was 0.09 L (range 0.17 to 0.45), 13.3%
(range 16.5 to 67.9) for BDRBASE, and 3.2% (range 4.4
to 15.2) for BDRPRED (Table 1). Correlation between
BDRABS and BDRBASE was 0.91, between BDRABS and
BDRPRED was 0.94, and between BDRBASE and BDRPRED
was 0.94 in NETT subjects. All subjects in NETT were
required to abstain from smoking for 4 months prior to
initial evaluation.25 The mean age of probands in the
Boston Early-Onset COPD Study was 48.1 years, and the
mean baseline prebronchodilator FEV1 was 19.2% predicted
(Table 1). Sixteen out of 127 early-onset COPD probandsTable 2 Genetic association results of bronchodilator responsiv
Associations for all three phenotypes are shown when any of the p
models included age, sex, and pack-years of smoking.
Gene SNP MAF Role BDRABSa
b (S.E.)
EPHX1 rs3753661 0.09 Intron 0.02 (0.01)
rs3766934 0.09 Intron 0.03 (0.01)
rs1009668 0.11 Downstream 0.02 (0.01)
SERPINE2 rs6712954 0.06 Exon 0.03 (0.01)
rs7588220 0.02 Intron 0.06 (0.02)
rs3795877 0.19 Intron 0.02 (0.01)
ADRB2 rs1042717 0.20 Exon 0.01 (0.01)
rs1042718 0.17 Exon 0.01 (0.01)
MAF, minor allele frequency.
a BDRABSZ postbronchodilator FEV1 prebronchodilator FEV1.
b BDRBASEZðpostbronchodilator FEV1prebronchodilator FEV1Þprebronchodilator FEV1  100
c BDRPREDZðpostbronchodilator FEV1prebronchodilator FEV1Þpredicted prebronchodilator FEV1  100(13%) were current smokers. Mean BDR phenotypes of
probands in the Boston Early-Onset COPD Study were
similar to those of NETT subjects (Table 1).
Association analysis in NETT subjects
As shown in Table 2, two SNPs in EPHX1 (rs3753661
pZ 0.02, rs3766934 pZ 0.02) and two SNPs in SERPINE2
(rs6712954 pZ 0.047, rs7588220 pZ 0.01) were signifi-
cantly associated with BDRABS. Three SNPs in EPHX1
(rs3753661 pZ 0.01, rs3766934 pZ 0.009, rs1009668
pZ 0.04 (Fig. 1)) and two SNPs in SERPINE2 (rs3795877
pZ 0.04, rs7588220 pZ 0.01) were associated with
BDRBASE. One SNP in EPHX1 (rs3766934 pZ 0.04), 3 SNPs in
SERPINE2 (rs6712954 pZ 0.04, rs3795877 pZ 0.03,
rs7588220 pZ 0.004) and 2 SNPs in ADRB2 (rs1042717
pZ 0.04, rs1042718 pZ 0.045) were associated with
BDRPRED. The Arg16Gly (rs1041713) and Gln27Glu
(rs1041714) polymorphisms in ABRD2 were not associated
with BDR phenotypes. SNPs rs3753661 and rs3766934 of
EPHX1 were in complete LD (r2Z 1.0). The three significant
SNPs in SERPINE2 were not in LD (r2< 0.1). SNPs in SFTPB,
TGFB1, and GSTP1 were not associated with BDR
phenotypes.
Replication in Boston Early-Onset COPD Study
Pedigrees
In order to assess replication of these associations, SNPs
in EPHX1, SERPINE2 and ADRB2 were analyzed in the
Boston Early-Onset COPD Study families. Among the
significantly associated SNPs in the NETT subjects, one
SNP downstream of EPHX1 (rs1009668) was associated
with BDRPRED (pZ 0.04), and one SNP in intron 1 of
SERPINE2 (rs7588220) was associated with BDRBASE
(pZ 0.003) in the EOCOPD families. However, the direc-
tion of effect of SERPINE2 SNP rs7588220 was noteness in subjects in the National Emphysema Treatment Trial.
henotypes had p< 0.05. Covariates included in the regression
BDRBASEb BDRPREDc
p b (S.E.) p b (S.E.) p
0.02 3.7 (1.5) 0.01 0.67 (0.35) 0.06
0.02 4.0 (1.5) 0.009 0.74 (0.36) 0.04
0.10 3.0 (1.4) 0.04 0.63 (0.35) 0.07
0.047 3.8(2.3) 0.09 1.11 (0.50) 0.04
0.01 9.2 (3.5) 0.01 2.44 (0.84) 0.004
0.08 2.8 (1.3) 0.04 0.72 (0.32) 0.03
0.14 1.3 (1.1) 0.24 0.52 (0.26) 0.04
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Figure 1 Bronchodilator response (BDRBASE) by rs1009668
coding SNP in NETT subjects. Mean values (þSEM) for change in
FEV1 as a percent of baseline FEV1 are shown (pZ 0.04).
BDRBASE; change in FEV1 as a percent of baseline FEV1.
Genetic influences on BDR 555consistent in the two studies. SNP rs7588220 is relatively
rare (minor allele frequencyZ 0.02) in EOCOPD families,
so there were only a small number of informative families
in PBAT analysis (nZ 3). EPHX1 SNP rs1009668 was asso-
ciated with reduced BDR in the two study samples. SNPs
in ADRB2 were not associated with BDR phenotypes in
EOCOPD families. However, rs1042713 (Arg16Gly) was
associated with BDRPRED (pZ 0.04) and BDRABS
(pZ 0.04) in subgroup with physician-diagnosed asthma
history in the EOCOPD families.
Because SNP rs1009668 was the only replicated SNP with
BDR across both populations, we examined associations with
FEV1 (% predicted) and chest CTemphysema. This SNPwas not
associated with FEV1 level, but it was associated with
increasedpercentemphysemaonchestCTscansat a threshold
of950 HU (bZ 0.04, pZ 0.009) in NETT subjects.
Haplotype analysis
Haplotype analysis using haplo.stats in NETT subjects and
using PBAT in EOCOPD families revealed associations similar
to those found in the single SNP analysis in EPHX1 (data not
shown). In ADRB2, haplotypes of rs1042713 (Arg16Gly) and
rs1042714 (Gln27Glu) were associated with BDRPRED in
NETT (global pZ 0.046), but this was not replicated in
EOCOPD families.
Discussion
In this study, we examined SNPs in 6 COPD candidate genes
including the ADRB2 gene, which has been reported to be
associated with bronchodilator responsiveness, and found
associations between bronchodilator responsiveness in
NETT subjects and SNPs in the EPHX1, SERPINE2, and ADRB2
genes. The association between one SNP in EPHX1 and
bronchodilator responsiveness was replicated in extended
pedigrees from the Boston Early-Onset COPD Study.
The product of EPHX1 is microsomal epoxide hydrolase,
which is important for the metabolism of cigarette smoke
by-products. In previous studies, the fast allele of EPHX1
(His139Arg, rs2234922) was found to be protective against
COPD in a caseecontrol study comparing NETT cases to
control smokers,9 protective against upper lobe predomi-
nant emphysema in NETT,17 and associated with improvedresponse to lung volume reduction surgery (LVRS), as
measured by BODE score.22 The slow allele of EPHX1
(Tyr113His, rs1051740) has been associated with emphy-
sema susceptibility26 and reduced lung function.27 Haplo-
type analysis of His139Arg and Tyr113His revealed
associations with rapid lung function decline in the Lung
Health Study.28 In NETT, other SNPs in EPHX1 have been
associated with exercise capacity, DLCO and response to
LVRS.21,22
The replicated SNP, rs1009668, was chosen because it is
downstream of EPHX1, but is actually located in exon 1 of
an adjacent gene, KIAA0792. The function of this gene
product is not known, but the gene has been shown to be
expressed in adenocarcinoma of the lung.29 This SNP results
in replacement of valine with methionine at amino acid
position 622. In COPD patients, lower BDR may be related to
more severe emphysema.4 This SNP (rs1009668), which was
associated with lower BDR, was also associated with
increased emphysema and may have a role in COPD path-
ogenesis. However, it is not clear whether this SNP
association is due to linkage disequilibrium with a func-
tional variant in EPHX1 or in KIAA0792.
An SNP in intron 1 of SERPINE2 (rs7588220) was associ-
ated with BDR in both NETT subjects and Boston Early-Onset
COPD Study families, although the directionality of associ-
ation was not consistent. This gene was associated with
COPD susceptibility in several COPD populations.11,30
However, the role of this gene in the pathophysiology of
COPD has yet to be identified. It is possible that SERPINE2
variants could define a subset of COPD patients with
differential bronchodilator responsiveness.
Two previous studies have investigated the association
between BDR and genetic polymorphisms in COPD. A recent
publication reported an association of BDR and poly-
morphisms of the b2-adrenergic receptor gene (ADRB2) in
246 Japanese patients with COPD.8 Arg16 genotypes and
Arg16eGln27 haplotypes were associated with decreased
BDR. This gene has been studied as a susceptibility gene for
asthma31 and COPD,12,13 and also for a direct role in drug
response.32 Studies in asthma suggest the Arg16 allele is
associated with greater acute bronchodilator responsive-
ness but decreased long-term response to regular use of
short-acting b2 agonists.14
In our study, there was association only with haplo-
types of the codon 16 and 27 polymorphisms in NETT
subjects, but this was not replicated in EOCOPD families.
In the EOCOPD families, the codon 16 polymorphism was
associated with BDR only in the subgroup of subjects with
a history of physician-diagnosed asthma. This suggests
that ADRB2 is not a major determinant of BDR in COPD,
but may be relevant in patients with an asthmatic
phenotype.
In another study,7 a polymorphism in the hemopoietic
cell kinase (HCK ) gene was associated with differential
expression of Hck protein and myeloperoxidase release
from polymorphonuclear leukocytes in 60 COPD patients.
This polymorphism was associated with BDR in 487
subjects from the Lung Health Study, suggesting that this
gene contributes to COPD pathogenesis and modifies BDR.
Because this gene was not associated with COPD
susceptibility, we did not include it in our candidate gene
panel.
556 W.J. Kim et al.The present study has several limitations. First, because
there is not a single optimal measurement for bronchodi-
lator responsiveness, we analyzed bronchodilator pheno-
types expressed in three ways. All three measurements
have their advantages and limitations, so we investigated
all three phenotypes and used a replication strategy in this
study to limit the possibility of false positive results.
Second, the replicated SNP association in EPHX1 was for
a different, but highly correlated, BDR phenotype in our
two study populations. Third, intra-individual variability in
response to bronchodilator33 may reduce power to detect
genetic associations, yet we were still able to identify SNP-
level replication for association between EPHX1 and BDR.
Fourth, the LD-tagging approach yielded SNPs that may not
be the specific functional variants. The associated SNPs
were intronic or in an exon of a gene with unknown func-
tion. The actual causal variant or variants remain to be
discovered. Fifth, multiple statistical comparisons are
a potential concern in any complex disease genetics study.
Though the optimal approach to adjust for multiple testing
is not clear, we used replication of the results in another
study sample to guard against false positive results.
The NETT subjects and the Boston Early-Onset COPD
probands all have severe airflow obstruction. Thus, the
applicability of our findings to mild-to-moderate COPD
patients may be limited. However, family members in the
Boston Early-Onset COPD Study had a broad range of lung
function values. Early-Onset COPD subjects likely represent
a unique subgroup of COPD patients. This could contribute
to lack of replication of our associations found in NETT.
In conclusion, polymorphisms of EPHX1, SERPINE2, and
ADRB2 were associated with bronchodilator responsiveness
phenotypes in one population of subjects with severe
COPD. BDR in COPD patients may depend upon different
disease subtypes, differences in drug metabolism, or other
pharmacogenetic effects. This study revealed that EPHX1 e
which has been previously associated with COPD suscepti-
bility, lung function and CT phenotypes e demonstrated
replication in a second population. BDR may be partly
explained by genetic factors. Future directions will include
replication in additional populations, identification of the
functional variant or variants, and determination whether
there are subtypes of COPD with differential bronchodilator
responsiveness.
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